Genelux Corporation $GNLX Shares Bought by LifeSteps Financial Inc.

LifeSteps Financial Inc. lifted its holdings in Genelux Corporation (NASDAQ:GNLX) by 13.6% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 97,219 shares of the company’s stock after acquiring an additional 11,627 shares during the quarter. LifeSteps Financial Inc.’s holdings in Genelux were worth $279,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in GNLX. Advisor Resource Council acquired a new position in shares of Genelux in the 1st quarter worth approximately $34,000. Liberty Wealth Management LLC acquired a new position in shares of Genelux in the 1st quarter worth approximately $45,000. 5T Wealth LLC acquired a new position in shares of Genelux in the 1st quarter worth approximately $49,000. American Century Companies Inc. acquired a new position in shares of Genelux in the 1st quarter worth approximately $51,000. Finally, Beacon Capital Management LLC grew its stake in shares of Genelux by 99.8% in the 2nd quarter. Beacon Capital Management LLC now owns 19,116 shares of the company’s stock worth $55,000 after purchasing an additional 9,550 shares during the last quarter. Institutional investors and hedge funds own 37.33% of the company’s stock.

Genelux Price Performance

Genelux stock opened at $4.71 on Wednesday. The firm’s 50 day simple moving average is $3.75 and its 200-day simple moving average is $3.14. The company has a market cap of $177.90 million, a P/E ratio of -5.48 and a beta of -0.22. Genelux Corporation has a fifty-two week low of $1.99 and a fifty-two week high of $5.89.

Genelux (NASDAQ:GNLX) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.02. On average, analysts expect that Genelux Corporation will post -0.88 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on GNLX. Wall Street Zen raised shares of Genelux from a “sell” rating to a “hold” rating in a research note on Saturday, July 12th. HC Wainwright reissued a “buy” rating on shares of Genelux in a research report on Wednesday, July 23rd. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Genelux in a research report on Saturday, September 27th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $20.33.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.